Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GBP510 with Alum in Healthy Adults
NCT04742738Phase 2Completed
- Sponsor
- SK bioscience
- Start
- Jan 2021
- Primary completion
- Jul 2021
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GBP510 + AS03 in coronavirus disease 2019 (COVID-19), sponsored by SK bioscience. Started Jan 2021; status: completed.
02
Drugs
GBP510 + AS03
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04742738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04742738.